Fate Therapeutics (FATE) Current Assets (2012 - 2026)

Fate Therapeutics' Current Assets history runs 15 years deep, the most recent figure standing at $179.5 million for Q1 2026.

• Quarterly Current Assets fell 27.67% year-over-year to $179.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.5 million (down 27.67% YoY) and the FY2025 annual result came in at $208.7 million, down 28.5% from the prior year.
• Current Assets was $179.5 million for Q1 2026 at Fate Therapeutics, down from $208.7 million in the prior quarter.
• Across five years, Current Assets topped out at $599.2 million in Q2 2022 and bottomed at $179.5 million in Q1 2026.
• A 5-year average of $362.7 million and a median of $331.5 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets declined 9.94% — and 2025, when it plunged 37.06%.
• Fate Therapeutics' Current Assets stood at $502.1 million in 2022, then sank by 33.97% to $331.5 million in 2023, then declined by 11.95% to $291.9 million in 2024, then slipped by 28.5% to $208.7 million in 2025, then slipped by 13.98% to $179.5 million in 2026.
• Business Quant data shows FATE's Current Assets at $179.5 million in Q1 2026, $208.7 million in Q4 2025, and $221.3 million in Q3 2025.